Sarah A.Geers

Associate

(T) 1.212.326.3936

Sarah Geers represents pharmaceutical clients in intellectual property litigation in a variety of venues, including in district court, arbitration, and at the PTAB. Her practice spans Hatch-Waxman and other patent infringement actions, inter partes review proceedings, trade secret and misappropriation actions, and patent prosecution strategy advice. In addition to intellectual property matters, she has litigated a variety of commercial disputes, including antitrust, securities, and fraud claims. Her litigation experience spans discovery, trial, and appeal.

Sarah was involved in the successful resolution of Hatch-Waxman litigation involving the transdermal patch Butrans(R) and continues to be involved in a plethora of patent infringement actions involving the pain medication OxyContin(R).

Sarah recently successfully represented a pro bono client in obtaining permanent resident status pursuant to a VAWA battered spouse waiver, in conjunction with the Her Justice program.

Before becoming an attorney, Sarah worked as a research chemist at Merck & Co., where she was responsible for solid dosage form development and associated preformulation research. While at Merck, she also participated as a patent department intern in patent prosecution and counseling. In addition, Sarah previously served for one year as a pro bono staff attorney at the New Jersey Institute for Social Justice in Newark, New Jersey.

Experience

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Intellipharmaceutics
Jones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of a Section 505(b)(2) New Drug Application to the FDA seeking approval of an extended-release oxycodone formulation.

Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Ascent related to OxyContin®
Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendant Ascent Pharmaceuticals, Inc., pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.

Adocia prevails in biopharma license agreement dispute in international arbitration
Jones Day won a binding arbitration award for French biopharmaceutical company, Adocia S.A., in a license agreement dispute against Eli Lilly and Company.

Purdue Pharma successfully moves for additional discovery regarding real-party-in-interest, leading to termination of IPRs before institution
Jones Day defended patent owner, Purdue Pharma L.P., in connection with two inter partes review (IPR) petitions brought by the petitioner, Kashiv Pharma, LLC, against U.S. Patent Nos. 9,492,392 and 9,492,393.

Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Epic Pharma related to OxyContin®
Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Epic Pharma, LLC and PuraCap Pharmaceutical LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of a generic version of OxyContin®.

Purdue Pharma successfully resolves Hatch-Waxman patent infringement claims against Amneal and Kashiv related to OxyContin®
Jones Day successfully represented Purdue Pharma L.P. in related Hatch-Waxman patent infringement actions against defendants Amneal Pharmaceuticals, LLC and Kashiv Pharma, LLC, pertaining to the submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Abhai
Jones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against the defendant, Abhai LLC's, submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed drug for pain relief.

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against Mylan
Jones Day successfully represented Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.

Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®
Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue.

Purdue Pharma asserts patent infringement claims under Hatch-Waxman Act related to OxyContin® against KVK-Tech and Abhai
Jones Day is representing Purdue Pharma L.P. in a Hatch-Waxman patent infringement action against defendants, relating to the defendants' submission of an Abbreviated New Drug Application to the FDA seeking approval of generic versions of OxyContin®, a widely prescribed treatment for pain relief.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.